Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions around the publication underscore significant findings, such as several participants citing the JUPITER trial's positive impact on cardiovascular events for patients with high hs-CRP but normal LDL levels. Phrases like 'statins provide benefit' and references to specific statistics, such as hazard ratios, illustrate the strong belief in the study’s conclusions. Additionally, some participants voiced skepticism regarding the methodology and potential biases, showcasing a mix of belief and critical analysis that enhances the overall discourse.
Many discussions reflect a general support for the publication's findings, although there are dissenting voices voicing skepticism.
The majority of users exhibited strong curiosity, with many posts analyzing the implications and findings of the study.
While several discussions displayed interest, the depth of engagement varied, with some posts engaging in detailed critique and analysis of the study.
Comments frequently assert that the findings have considerable implications for cardiovascular health, indicating a strong belief in the study's impact.
Interestingly, the reduction in heart disease seen with many statins in clinical trials may stem as much from their anti-inflammatory effects as their reduction in cholesterol synthesis, this study found positive effects even in those with normal LDL https://t.co/tqUNki23Go
JUPITER (non-HIV high hsCRP rosuvastatin vs placebo trial https://t.co/0V02bgPTIe) was also terminated early for overwhelming efficacy. Now the second time a trial of pts with high inflammatory risk shows particularly high benefit from statins. [2/3]
@1NoCaGal If your LDL is high, but all other markers or risk factors for heart disease are great, then you do not likely need to change anything. Even Big Pharma scientists recognize you don’t need a statin. https://t.co/QWnS07wV5H… https://t.co/qrTaNXfKBI
@venkmurthy @bengoldacre @COMPare_Trials This is amazing work. I’ve always wondered why @NEJM and JUPITER investigators never published the result of CV death, which was one of the primary endpoints. https://t.co/FUifpc6AMR https://t.co/9agQybiRQx
4/ JUPITER (primary prevention with rosuvastatin in people with elevated hs-CRP): "Death from any cause (hazard ratio, 0.80; 95% CI, 0.67 to 0.97; P=0.02)." https://t.co/k5iWb6BaJz https://t.co/MO2fHHvXvj
Luego llego JÚPITER en donde se trabaja con Rosuvastatina, encontrando como resultado un RR de 56% y con un LDL inferior a 50 mg/dL disminuye el RR hasta un 35% (con fármacos como la pravastina, el RR oscila entre un 76%) DOI: 10.1056/NEJMoa0807646
In this video, Dr. Sten Ekberg's cholesterol claims are critically analyzed against scientific evidence. Bempedoic acid, an ATP citrate lyase inhibitor, effectively reduces LDL cholesterol with fewer side effects…
This video discusses the effectiveness of rosuvastatin in preventing cardiovascular events in healthy individuals with high C-reactive protein levels. The study showed that rosuvastatin significantly reduced LDL…
Do statins cause diabetes? This video explores how factors like dosage and type influence diabetes risk in statin users, emphasizing the potential benefits for cardiovascular health versus the risk of new-onset…
In this video, we delve into the spread of nutrition misinformation, particularly focusing on Dr. David Diamond's stance on low carbohydrate diets and statin therapy. His perspectives challenge traditional guidelines…
This video explores whether rosuvastatin can prevent cardiovascular events in healthy individuals with high C-reactive protein levels. It highlights the study's findings on lower rates of heart attacks and strokes…
Intraplaque hemorrhage is common in advanced coronary atherosclerotic lesions and may contribute to plaque vulnerability by increasing free cholesterol from erythrocyte membranes, leading to larger necrotic cores and…
This video explores the misconception that cholesterol is the primary cause of heart disease. It discusses how intraplaque hemorrhage contributes to plaque vulnerability by increasing free cholesterol, leading to plaque…
Intraplaque hemorrhage is common in advanced coronary lesions and may contribute to plaque vulnerability by increasing free cholesterol from erythrocyte membranes, leading to larger necrotic cores and greater macrophage…
@bob712bob @crazieyfox @Pl4ntbased Here are two 'primary' trials. One is Jupiter - the trial which got rosuvastatin approved. https://t.co/03BFtSfiuj The other is a mendelian genetic randomized study which shows each std deviation higher genetic LDL results in 1.2 years short life. https://t.co/Xf8dq5jgQj https://t.co/uoLJ7lRnZA
@1NoCaGal If your LDL is high, but all other markers or risk factors for heart disease are great, then you do not likely need to change anything. Even Big Pharma scientists recognize you don’t need a statin. https://t.co/QWnS07wV5H… https://t.co/qrTaNXfKBI
If your LDL is high, but all other markers or risk factors for heart disease are great, then you do not likely need to change anything. Even Big Pharma scientists recognize you don’t need a statin. https://t.co/DiQDxwubbV https://t.co/tDjIhIXec7
@MarketPicker @MohammedAlo I am only aware of data suggesting that the healthy people you speak of do not benefit from a statin. https://t.co/VEy3LbTapb https://t.co/EO9f3lm95k
JUPITER試験2008年報告書で statin群心筋梗塞
@soonergise @AdamLakeNoble @realDaveFeldman
@AdamLakeNoble @DrEricRodgers @realDaveFeldman https://t.co/ZHKG5xetVX https://t.co/h6MKW6p1gc
https://t.co/2i5iOzGf9G https://t.co/DiQDxwubbV
@0372Sandy @johnrich Here is just one of the MANY high clinical trials of statins. Do you actually believe that you can faithfully interpret the study design, analytic methods, measures of effect, strengths, limitations, and next steps? That's a two year degree bare minimum. https://t.co/jTDJKYW9th
@healthy_profits @ifixhearts https://t.co/jTDJKYW9th
@offofthecouch @DoctorTro I'm not sure you read the trial. https://t.co/BS6uu5y9Mc https://t.co/P1KQ4pedya
@JakeMat91 Also a reduction in death from any cause was also noted in the original study. https://t.co/fbNLgZLIz8 https://t.co/03vj0zrTqe
@dylanarmbruste3 @JakeMat91 Yep. "The stopping boundary was crossed at the first prespecified efficacy evaluation " https://t.co/fbNLgZLIz8
@SBakerMD Median Hba1c between statin and placebo was 0.1%. Give me a break. https://t.co/IUYz2oOr1C
@LysanderBoomer @NoLongerBennett @BrowningMachine The Jupiter study showed a decrease in all-cause mortality: https://t.co/Z2X75EEDet
@FatEmperor @nicewhendone No they didn't fail. High dose vs. normal dose may not give benefit. But statins vs. placebo do show benefit. And the Vioxx scandal shows that there is a price to pay for bringing bad drugs to the market. https://t.co/uXFtTZUAps
RT @adamfc2000: @mumzles1 @NunThewyser @dontdelay The graphic is from the JUPITER trial but pretty much every study on statins shows the sa…
@mumzles1 @NunThewyser @dontdelay The graphic is from the JUPITER trial but pretty much every study on statins shows the same thing. https://t.co/zUmVr1j8gE
@nntaleb @Drlipid In the JUPITER trial in "apparently healthy men and women" there was a reduction in all-cause mortality. https://t.co/c1dug8gSEo @JohnKastelein can maybe tell us more? https://t.co/dHjLJAS3hc
2008年JUPITER試験 statin→糖尿発症risk有意⬆️初報告大規模ランダム化試験 https://t.co/xHzWwkAwZV 17,802人 LDL正常,高感度CRP(hsCRP)⬆️患者で心血管event予防でRosuvastatin有効性を評価目的の治験 Rosuvastatin群で医師報告の糖尿発症率25％⬆️ 糖尿病報告270件 vs プラセボ群216件
@primalpoly Statins lower MI risk regardless of cause. See Rosuvastatin trial in ppl w low cholesterol ⬇️ but high inflammation. So assess your risk, then decide: A) use full Framingham risk calculator (family history, …) And/or B) get Coronary Calcium Scan. https://t.co/ytMfHczMQm
4/ JUPITER (primary prevention with rosuvastatin in people with elevated hs-CRP): "Death from any cause (hazard ratio, 0.80; 95% CI, 0.67 to 0.97; P=0.02)." https://t.co/k5iWb6BaJz https://t.co/MO2fHHvXvj
@turnbullissimo @dr_cois https://t.co/YeGmSmlcKM https://t.co/44oRSpETSF https://t.co/UTkB55ktmT
Een significante toename van nieuwe diabetes na gemiddeld 1,9 jaar bij gebruik van statines voor #chloresterol https://t.co/bTargcL131 https://t.co/RlmbFRKEqf
Referanslar: https://t.co/vmZhd1gd9i https://t.co/88PPKAUePg https://t.co/vjBAcaSN7K https://t.co/gVsSTOKS8L
Rosuvastatina per prevenire eventi vascolari in uomini e donne con elevata proteina C-reattiva Elenco degli autori. Dott. Paul M. Ridker,Eleanor Danielson, MIA,Dott. Francisco AH Fonseca,Jacques Genest, medico,et al.,per il Gruppo di Studio JUPITER https://t.co/jqQL7gfegi
@BrianGurwitz @Drlipid https://t.co/HKL522YBoo
Critics raised concerns over the interpretation & veracity of the JUPITER trial and felt that the author's financial COIs revealed an unacceptable degree of commercial bias. 9 of 14 authors took money from @AstraZeneca, the drug maker and trial sponsor. https://t.co/PQkvjRCoB6
@drtanmoy Please post a study showing higher ASCVD rates. JUPITER was a large study of people who don't even have high LDL therefore should be MORE sensitive to your "cause" yet the rates were lower with rosuvastatin. https://t.co/H9Spev0DU5
3/ RCTs have shown that among individuals with evidence of systemic inflammation (elevated CRP), statins can reduce risk of cardiovascular events: https://t.co/n7cXnOWoFs
@Fynnderella1 @ArcangeliJames @MdBreathe @HEB You asked for one RCT: Here are several. Now will you apologize and admit to peddling ridiculous conspiracy GARBAGE? DOI: 10.1056/NEJMoa1600176 DOI: 10.1161/CIRCULATIONAHA.109.906479 DOI: 10.1056/NEJMoa0807646 DOI: 10.1016/S0140-6736(04)16895-5
@SimmonsBart https://t.co/gpTkxSn86O
@Uk4Lif @docjoe77 @RFRedberg There is no strong research result that statins yield objective benefits in 1° prevention; e.g., JUPITER did *not* show benefit of rosuvastatin vs placebo for objective criteria. (Pre-specified outcome in JUPITER included criteria that were subjective.) https://t.co/9Ubqpdohng
RT @cardiomet_CE: 14) Next, in patients with evidence of #inflammation as defined by #hsCRP >2 mg/dl, the #JUPITER trial showed a benefit o…
14) Next, in patients with evidence of #inflammation as defined by #hsCRP >2 mg/dl, the #JUPITER trial showed a benefit of high-intensity (20 mg) rosuvastatin
@Jonatha98829578 @RFRedberg Upper CI’s below one. Here’s another primary prevention trial - JUPITER - with stroke hazard ratio 0.52, p-value 0.002. All cause death HR 0.80. Genetic data suggest benefit of LDL-C/apoB lowering increases over time. https://t.co/XqU4kYMKbO https://t.co/eRLHdhAPfc
@drpablocorral How do you explain this study? https://t.co/tKLbf8Uxvd "... low high-sensitivity C-reactive protein levels would have been not only infeasible in terms of statistical power and sample size but also highly unlikely to show a benefit."
@ChristofferBN The initial publication was the following: https://t.co/QAvj48GFDe
@StevenMBelknap @gildone84 @Drlipid Happy to hear you feedback: https://t.co/82ORQI83jU Jupiter=Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin
@SaulNutri Como no Saul, existe una montaña de evidencia de reducción de IAM, revascularización y muerte CV...ademas de mortalidad total...y en prevención primaria...pero la desinformación la ha minado...te paso un RTC y algunos metanalisis https://t.co/9fROGzH5xz
@j_t_2390 @dylanarmbruste3 @Tellit007 @Drlipid https://t.co/BS6uu5y9Mc Those are hazard ratios. 44% reduction. Are you going to argue that too? How do you not know how to critically think about research? https://t.co/MGIzcSxauL
RT @pnatarajanmd: JUPITER (non-HIV high hsCRP rosuvastatin vs placebo trial https://t.co/0V02bgPTIe) was also terminated early for overwhel…
JUPITER (non-HIV high hsCRP rosuvastatin vs placebo trial https://t.co/0V02bgPTIe) was also terminated early for overwhelming efficacy. Now the second time a trial of pts with high inflammatory risk shows particularly high benefit from statins. [2/3]
RT @THEMightlyMouse: @KissMyCarol Jupiter Trial https://t.co/UzQVWnGUFA
@KissMyCarol Jupiter Trial https://t.co/UzQVWnGUFA
@DaleWil39870290 @aricarbins @wcu98 @ifixhearts No benefit of lowering trigs (fibrate trial last year) https://t.co/nHh44HW86i No benefit of raising HDL (multiple trials on CETP inhibitors) https://t.co/bgPBd6OgpW Great benefit of lowering LDL (JUPITER trial) https://t.co/neildyItZ4
@onphel @Lpa_Doc Those levels are way too high to be worth looking at; I doubt there are even trials that have looked at participants with an average LDL of that high. But have you looked at the JUPITER trial? https://t.co/5MzW0vMdUr
@edurontoFF @lamelaspablo @drpablocorral @LipidosSal @SAC_54 @clinicasac @SACcardiometab1 @CONAREC_ORG @SIAC_cardio @ComunidadFAC No lo sé Ernesto, en el Jupiter Rosu se asoció con mejoría la fx renal (eGFR) a 12m (al compararla con placebo) https://t.co/EsYvtHWDmQ Me parecería interesante evaluar las caract basales de cada grupo y pensar cuál sería la tasa de eventos renales si no se prescribiera estatina
https://t.co/Vh0mD69Gwo
@erudenko Вот ссылка на исследование, вы почитайте. Я не знаю, что мне комментировать. То что исследование было завершено раньше срока из-за достоверно высокой разницы в сс осложнениях или то, что это не понравилось некоторым учёным? Скажите что вам не понравилось https://t.co/YOn1UgwaCO
RT @ck_eternity_: Interestingly, the reduction in heart disease seen with many statins in clinical trials may stem as much from their anti-…
Interestingly, the reduction in heart disease seen with many statins in clinical trials may stem as much from their anti-inflammatory effects as their reduction in cholesterol synthesis, this study found positive effects even in those with normal LDL https://t.co/tqUNki23Go
The claim that inflammation causes heart disease also has a kernel of truth. JUPITER, in particular, showed that when people with high levels of inflammation but normal cholesterol still benefit from taking a statin (which has anti-inflammatory effects). https://t.co/uNmLDFqnjK
@kinroito @rakusuke1990 ①カプランマイヤーでは、グラフが真っ平になるのは不思議ではないかと。 https://t.co/VBOXyqbP5W ②元の論文を見ると、縦軸は合っていますよ https://t.co/RP7de54nBG 間違い有れば教えていただけると幸いです。
https://t.co/qa3iBOMcpR
@AlbertoDiazGa10 @maria_dhg Hay un par de referencias a ella https://t.co/tp7xVY59IJ https://t.co/iMFB8ZuiLN
@Earthling637 27. Örneğin meşhur JUPITER çalışması kalp hastalığı, yüksek kolestrol geçmişi olmayan ama yüksek hsCRP değeri olanlarda statin kullanmanın vefat oranlarını düşürdüğünü iddia etmektedir. [6]. https://t.co/GMF96fCHpl [7]. https://t.co/ZIq0aPRsRf [8]. https://t.co/yyVsmZuAx2
@sorahill "the JUPITER trial showed statins provided benefit in those who had no history of high cholesterol or heart disease, but only elevated high-sensitivity C-reactive protein (hsCRP) levels, an indicator for inflammation." https://t.co/0VNiLeWT7c
@HL327 @stephensenn @f2harrell This change happened from lipid focus to risk-based statin started over a decade ago, lots of RCTs. Jupiter trial, healthy patients with without hyperlipidemia has reduction in CVD events with statins: https://t.co/pvgVMqQl5n
1/5: Anyone concerned (@accpcardprn) that #bempedoicacid touts ⬆️ tolerance vs. statins by citing RCT when the concern has been that AEs aren’t fully captured in RCTs? JUPITER showed no ⬆️ myalgia w/ rosuva vs. PBO. Very different from PRIMO https://t.co/hGDZKPyuFz
@PearlF @rabois @skathire Oh I’m not sure my poor brain can handle COVID and statins at the same time... https://t.co/xCpgddCpHf
La teoría inflamatoria esta planteada hace un buen tiempo. Tal vez el antecedente más importante empezó con el estudio JUPITER, que utilizó estatina en pacientes con LDL < 130 mg/dL y PCR > 2.0 mg/L. https://t.co/6SRbQLy2bk
Individuals with normal lipid profiles but elevated C- reactive protein, #rosuvostatin significantly reduce the incidence of CV invents. #Cardiovasclar, #MI, #Statin, #Stroke https://t.co/3RbsizQaVJ
@NutritionMadeS3 https://t.co/t1oBSKfyXi
RT @leticiakawano: @ryanboente @awtpulmdoc @EmmGeezee @JKropski @drdayjee The effect size is not bad...Let´s think that it took only some h…
@ryanboente @awtpulmdoc @EmmGeezee @JKropski @drdayjee The effect size is not bad...Let´s think that it took only some hundred patients to demonstrate a positive effect. Think of Cardiology trials, why they need to enroll 20k pts? Because the effect size they are willing to dectect is tiny little! 3/ https://t.co/q184yZwxOG
RT @SusanaFortichS: Luego llego JÚPITER en donde se trabaja con Rosuvastatina, encontrando como resultado un RR de 56% y con un LDL inferio…
Luego llego JÚPITER en donde se trabaja con Rosuvastatina, encontrando como resultado un RR de 56% y con un LDL inferior a 50 mg/dL disminuye el RR hasta un 35% (con fármacos como la pravastina, el RR oscila entre un 76%) DOI: 10.1056/NEJMoa0807646
#Jupitar2008 randomized 17802 individual, age >50 y, LDL<130 and CRP> 2mg/dl to placebo and rosuvastatin 20 mg. The results were significant reduction in the CVDs to the statin group. https://t.co/ol83d8wUHc
RT @puddleg: @lamelaspablo @DrScottMurray @erreyedoc @drpablocorral @ProfKausikRay @lipiddoc @Drlipid @rblument1 @pabeda1 @rauldsf_santos H…
@lamelaspablo @DrScottMurray @erreyedoc @drpablocorral @ProfKausikRay @lipiddoc @Drlipid @rblument1 @pabeda1 @rauldsf_santos Here's a Jupiter chart - HR 0.55 on placebo with highest HDL. HR for statin vs placebo in whole Jupiter trial was 0.56. https://t.co/YdiSAMYZd7 https://t.co/YzxKT5s69Q
@dlifein @omlakhani you can read the study for yourself here. https://t.co/Y81CVWl0gQ
RT @drjohnm: @venkmurthy @bengoldacre @COMPare_Trials This is amazing work. I’ve always wondered why @NEJM and JUPITER investigators never…
RT @drjohnm: @venkmurthy @bengoldacre @COMPare_Trials This is amazing work. I’ve always wondered why @NEJM and JUPITER investigators never…
RT @drjohnm: @venkmurthy @bengoldacre @COMPare_Trials This is amazing work. I’ve always wondered why @NEJM and JUPITER investigators never…
RT @drjohnm: @venkmurthy @bengoldacre @COMPare_Trials This is amazing work. I’ve always wondered why @NEJM and JUPITER investigators never…
RT @drjohnm: @venkmurthy @bengoldacre @COMPare_Trials This is amazing work. I’ve always wondered why @NEJM and JUPITER investigators never…
RT @drjohnm: @venkmurthy @bengoldacre @COMPare_Trials This is amazing work. I’ve always wondered why @NEJM and JUPITER investigators never…
@venkmurthy @bengoldacre @COMPare_Trials This is amazing work. I’ve always wondered why @NEJM and JUPITER investigators never published the result of CV death, which was one of the primary endpoints. https://t.co/FUifpc6AMR https://t.co/9agQybiRQx